欢迎来到天天文库
浏览记录
ID:52005689
大小:417.93 KB
页数:6页
时间:2020-03-21
《半抗原DNP修饰自体肿瘤疫苗治疗晚期恶性黑色素瘤的临床研究.pdf》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、中国癌症防治杂志2014年9月第6卷第3期ChinJofOncolPrevandTreat,Sep2014,~o1.6,No.3·247·DNP修饰自体肿瘤疫苗治疗晚期恶性黑色素瘤的临床陈殿君李晓松赵辉付艳胡佳祁楠石秀丽杜楠作者单位:100048北京解放军总医院第一附属医院肿瘤二科【摘要】目的探讨半抗原二硝基氟苯(dinitrophenyl,DNP)修饰自体肿瘤疫苗在晚期恶性黑色素瘤治疗中的作用。方法84例Ⅲ期或Ⅳ期可切除恶性黑色素瘤患者随机分为半抗原DNP修饰瘤苗组和半抗原DNP未修饰瘤苗组,每组42例,分别采用半抗原DNP修饰的自体肿瘤疫苗和半抗原DNP未修饰的自体瘤苗
2、联合化疗进行治疗,采用流式细胞技术检测两组患者外周血CD4+CD25调节性T细胞(regulatoryTcell,Treg)数量及淋巴细胞亚群的变化,观察迟发型超敏反应(delayedtypehypersensitivity,DTH)及随访生存情况。结果治疗后半抗原DNP修饰瘤苗组患者CD4+-IFN一、CD8+-IFN一淋巴细胞亚群较治疗前及半抗原DNP未修饰瘤苗组明显升高(P均<0.05),而CD4+GD25*Treg数量减少(0.05),半抗原DNP未修饰瘤苗组治疗前后无明显变化(0.05);半抗原DNP修饰瘤苗组患者较半抗原DNP未修饰瘤苗组DTH明显增强,硬结明显
3、增大,两组DTH达到阳性结果(I>5mm)的百分比分别为94.6%和45.0%(尸<0.05o半抗原DNP修饰瘤苗组患者1年、2年和3年生存率分别为95.0%、73.O%和65.5%,总生存率(overallsurvival,OS)为79.3%,无疾病生存率(diseasefreesurvival,DFS)为81.1%;半抗原DNP未修饰瘤苗组患者1年、2年和3年生存率分别为90.1%、59.O%和435%,OS为64-2%,DFS为74.0%,两组患者生存时间差异有统计学意义(P4、制机体免疫耐受,从而延长患者生存时间。【关键词】恶性黑色素瘤;二硝基氟苯;半抗原;肿瘤疫苗;免疫治疗【中图分类号】R739.5【文献标志码】A【文章编号】1674—5671(2014)03—06DOI:10.3969/j.issn.1674—5671.2014.03.06Clinicalstudyofdinitrophenyl-modifiedautologoustumorvaccinetotreatadvancedmalignantmelanomaCHENDian-jun,LIXiao-song,ZHAOHui,FUYan,HUJia,QINan,SHIXiu—li,DU5、Nan(TheSecondDepartmentofOneology,TheFirstAfiliatedHospitalofChinesePLAGeneralHospital,Beijing100048,P.R.China)Correspondingauthor:DUNan.E—mail:dunan05@aliyun.COB【Abstract】0bjectiveToinvestigatetheeficacyofautologoustumorvaccinemodifiedtocarrythedinitrophenylhaptentotreatadvancedmalignantm6、elanoma.MethodsClinicaldatawereretrospectivelyanalyzedfor84patientswhounderwentresectionforstageⅢb.1lIeorIVmalignantmelanomas.Patientsweredividedintotwogroupsdependingonwhetherornottheirbiochemotherapywassupplementedwithdinitrophenyl—modifiedautologoustumorvaccine.Thetwogroupswerecomparedi7、ntermsofthefollowingparameters:relativenumbersofCD4CD25regulatoryTcellsandlymphocytesubsetsinperipheralblood,whichweredeterminedusingflowcytometry;obseⅣedstrengthofdelayedtypehypersensitivity(DTH);andclinicaloutcomessuchasoverallsurvival(OS)anddisease—freesurv
4、制机体免疫耐受,从而延长患者生存时间。【关键词】恶性黑色素瘤;二硝基氟苯;半抗原;肿瘤疫苗;免疫治疗【中图分类号】R739.5【文献标志码】A【文章编号】1674—5671(2014)03—06DOI:10.3969/j.issn.1674—5671.2014.03.06Clinicalstudyofdinitrophenyl-modifiedautologoustumorvaccinetotreatadvancedmalignantmelanomaCHENDian-jun,LIXiao-song,ZHAOHui,FUYan,HUJia,QINan,SHIXiu—li,DU
5、Nan(TheSecondDepartmentofOneology,TheFirstAfiliatedHospitalofChinesePLAGeneralHospital,Beijing100048,P.R.China)Correspondingauthor:DUNan.E—mail:dunan05@aliyun.COB【Abstract】0bjectiveToinvestigatetheeficacyofautologoustumorvaccinemodifiedtocarrythedinitrophenylhaptentotreatadvancedmalignantm
6、elanoma.MethodsClinicaldatawereretrospectivelyanalyzedfor84patientswhounderwentresectionforstageⅢb.1lIeorIVmalignantmelanomas.Patientsweredividedintotwogroupsdependingonwhetherornottheirbiochemotherapywassupplementedwithdinitrophenyl—modifiedautologoustumorvaccine.Thetwogroupswerecomparedi
7、ntermsofthefollowingparameters:relativenumbersofCD4CD25regulatoryTcellsandlymphocytesubsetsinperipheralblood,whichweredeterminedusingflowcytometry;obseⅣedstrengthofdelayedtypehypersensitivity(DTH);andclinicaloutcomessuchasoverallsurvival(OS)anddisease—freesurv
此文档下载收益归作者所有